A 16-year-old girl presented to the emergency department (ED) with an anaphylactic reaction to a bee sting on the right side of her neck. Within 15 minutes of her arrival, swelling, numbness, and pain developed at this site. She also had headache, shortness of breath, and vague abdominal pain associated with nausea.
Figure 2 – Liver biopsy specimens showed nodule formation, encircling fibrosis, and brown pigment deposition (A, hematoxylin and eosin, ×40); fibrotic bands and disrupted liver lobules (B, trichrome, ×40); regenerative nodule formation (C, reticulin, ×40); marked iron deposits in the liver nodules (D, Prussian blue, ×40); and dense hepatocellular iron deposits (E, Prussian blue, ×400).
The patient, an average student and avid cheerleader, had not yet started menses. Four months earlier, she had received a diagnosis of type 1 diabetes mellitus and started taking insulin. She had no family history of consanguinity or iron overload disorders. Her 3 older sisters and 1 brother were healthy.
Height was 5.1 ft (1.52 m; 5th percentile); weight, 105.6 lb (48 kg; 10th percentile); and body mass index (BMI), 20.8 kg/m2 (50th percentile). Temperature was 36.6°C (98°F); blood pressure, 101/52 mm Hg; heart rate, 40 beats per minute; respiration rate, 17 breaths per minute, and oxygen saturation, 98% on room air.
The patient had right-sided neck and face swelling as well as diffuse skin hyperpigmentation. Heart sounds were normal, with bradycardia; pulmonary findings were also normal. The abdomen was soft, without organomegaly. External genitalia and breasts were Tanner stage III and II, respectively. Remaining physical findings were unremarkable.
An ECG showed evidence of third-degree heart block with a ventricular rate of 50 beats per minute (Figure 1). The patient was admitted to the pediatric ICU and treated with corticosteroids, antihistamines, and insulin.
A complete blood cell count and electrolyte and liver enzyme levels were normal. The hemoglobin A1c level was 9.7% (range, 4% to 6%). Other abnormal laboratory values included the following: serum iron, 207 μg/dL (range, 50 to 180 μg/dL); serum ferritin, 1109 ng/mL (range, 7 to 80 ng/mL); transferrin saturation, 83.5% (range, 20% to 50%); total thyroxine, 4.7 μg/dL (range, 4.9 to 12.2 μg/dL); cortisol, 2.6 μg/dL (range, 7 to 30 μg/dL); follicle-stimulating hormone, 0.2 mIU/mL (range, 6 to 13.8 mIU/mL); estradiol, less than 8 pg/mL (range, 10 to 200 pg/mL). Insulinlike growth factor (IGF), IGFI, and IGF-II levels were 102 ng/mL (range, 182 to 780 ng/mL), 79 ng/mL (reference, 469 ng/mL), and 93 ng/mL (reference, 491 ng/mL), respectively; IGF-binding protein level was 0.8 mg/L (reference, 3.8 mg/L). The iron-binding capacity and serum ceruloplasmin level were normal.
A chest radiograph showed cardiomegaly with mild pulmonary vascular congestion. Echocardiography showed global hypokinesia with a nondilated left ventricle and a shortening fraction of 0.20. Radiographs of the wrists and hands revealed the bone age to be about 13.5 years. MRI scans of the pituitary gland revealed areas of low signal on the T1-weighted images with inhomogeneous enhancement. MRI scans of the chest and abdomen showed persistent decreased signal of the myocardium, particularly the left ventricle and the interventricular septum, as well as of the liver and the pancreas. The combination of these findings led to the presumptive clinical diagnosis of hemochromatosis.
The patient underwent a percutaneous liver biopsy, which revealed portal fibrosis, bridging and encircling fibrosis, and cirrhosis (Figure 2). Hepatic iron quantitation was 23,692 μg/g (range, 50 to 1850 μg/g) and hepatic iron index, 26.5 μmol/g/y (reference, less than 1.9 μmol/g/y). Results of testing for the 2 HFE mutations (C282Y/H63D) associated with hereditary hemochromatosis (HH) were negative. Although testing for juvenile hemochromatosis (JH) mutations was not available at the time, JH with cardiomyopathy was diagnosed on the basis of the clinical features and findings from the echocardiography, iron studies, and liver biopsy.
1. Camaschella C, Roetto A, De Gobbi M. Juvenile hemochromatosis. Semin Hematol. 2002;39:242-248.
2. Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe juvenile hemochromatosis (JH). Blood. 2007;109:362-364.
3. Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: a life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet. 1983;65:149-154.
4. De Gobbi M, Roetto A, Piperno A, et al. Natural history of juvenile haemochromatosis. Br J Haematol. 2002;117:973-979.
5. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet. 2004;36:77-82.
6. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
7. Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology. 2005;128:470-479.